echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily Lilly terminates the new coronal and antibody ACTIV-3 study

    Research and development daily Lilly terminates the new coronal and antibody ACTIV-3 study

    • Last Update: 2020-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.10.27 Research and Development NEWS: Novartis potential "first-in-class" oral therapy medium-term clinical results are positive; Kangfang BioCD73 monoantigen in New Zealand completed the first health subject administration; AXA Pharmaceutical MDM2-p53 inhibitor APG-115 approved by China IB/II clinical trial; Four Rings Pharmaceuticals exclusive agent Botox Letti was approved for listing by NMPA... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original article) (Drug Development) Novarian's potential "first-in-class" oral therapy mid-clinical results positive Novaral today announced that its target complement signaling pathway of the potential "first-in-class" oral therapy iptacopan (LNP023), in the treatment of patients with C3 renal trophic patients in Phase 2 clinical trials, obtained positive mid-term clinical results.
    significantly reduced proteinuria levels in patients with C3G.
    IDH1 inhibitor registration trial topline results positive AML patient full remission rate of up to 30% Forma announced today that it obtained positive topline data in a mid-term analysis of a registered Phase 2 clinical trial in the study of IDH1 selective inhibitor olutasidenib.
    patients with R/R AML with IDH1 mutation were well-to-do with The Single Drug Treatment of Olutasidenib, with a compound complete remission rate of 33.3% for the main therapeutic endpoint, of which CR was 30%.
    Kangfang BioCD73 Monoantitor in New Zealand completed the first health subject drug administration Kangfang Bio recently announced its own research and development of innovative drug CD73 monoclonal antibody AK119 in a clinical trial in New Zealand completed the first health subject administration, AK119 is intended to be used to treat new coronavirus (COIVD-19) patients.
    Lilly terminated the new coronal median antibody ACTIV-3 study on the 26th, Lilly issued a statement to terminate the ACTIV-3 clinical study, the latest data of the study show that its new coronal and antibody LY-CoV555 (bamlanivimab) is unlikely to improve the late recovery of hospitalized COVID-19 patients.
    Drug Approval: Kangfang BioPharma's single anti-three-line treatment of nasopharyngeal cancer was approved by the FDA fast-track eligibility 27, Kangfang Bio and China Biopharmaceutical Co., Ltd. jointly announced that Pian puli (AK105) for third-line treatment of metastatic nasopharyngeal cancer has been granted by the FDA fast-track approval channel qualification (FTD).
    fda's award of fast-track eligibility significantly supports and accelerates The Amplify's business expansion program in the United States.
    Eglin Pharmaceuticals' third IND in a month was declared successful in the FDA! On October 27, Shenzhen Eglin Pharmaceutical Co., Ltd. announced that the U.S. FDA had approved the company's injection drug for the treatment of neo-coronavirus pneumonia, EG-009A clinical phase II trial application on October 26, EST.
    application for the IND was made under the FDA's special CTAP procedure for new coronavirus pneumonia.
    Gene Therapy PBGM01 was recognized by EMA Orphan Pharmaceuticals as a pilot gene therapy candidate drug for the treatment of GM1 neurostresside (GM1) by Passage Bio (NASDAQ: PASG) on the 26th.
    AXA Pharma MDM2-p53 inhibitor APG-115 has been approved for phase IB/II clinical trials in China, assailant pharma announced today that the company's class 1 new drug MDM2-p53 inhibitor APG-115 has obtained CDE clinical approval and will conduct a joint PD-1/PD-L1 inhibitor to treat patients with advanced liposarcoma or other advanced solid tumors in phase IB/II clinical studies.
    Boya because of the submission of the country's first CRISPR gene editing therapy clinical trial application 27, Boya because announced that the State Drug Administration Drug Review Center has accepted its blood transfusion-dependent β thalassemia gene editing therapy product ET-01, that is, CRISPR/ Cas9 gene modification BCL11A red line enhancer auto-CD34 plus hematocyte injection application.
    Tecentriq and Beva Zhu single-line treatment of liver cancer will be approved in China on the 26th, Roche submitted in China Tecentriq 2nd adaptive drug listing application into the "in-approval" stage, is expected to be officially approved in the near future, for the joint Beval Pearl single anti-treatment has not been systematic treatment of non-removable liver cell carcinoma (HCC) patients.
    Ted Pharmaceuticals Class 1 new drug was approved clinically 26, CDE publicity, Ted Pharmaceuticals Class 1 new drug TDI01 tablets obtained clinical trial implied license, intended to be developed for the treatment of idiotic pulmonary fibrosis.
    TDI01 is a new target ROCK2 highly selective inhibitor, which has therapeutic effects on all aspects of fibrosis development, and clinically intends to develop adaptations including non-alcoholic fatty hepatitis and pulmonary fibrosis.
    Seven Ring Pharmaceuticals exclusive agent Botulinum Toxin Le Tishon was approved by NMPA on the 26th, Four Rings Pharmaceuticals announced that by the company's sole agent, Korean biopharmaceutical company Hugel produced "injection of type A botulinum toxin (Letybo 100U, product name: Lotte) " on October 21, 2020 was officially approved by the State Drug Administration listed, becoming the fourth approved to list in China type A botulinum toxin, is also the first of its kind in South Korea.
    Colum will take 1.9 billion anaesthetic 2 first imitation on the road 26, Colum Pharmaceuticals propofol / long-chain fat emulsion into the administrative approval stage, the product belongs to the nervous system drugs in the anesthetic.
    currently, the nervous system area of Colum Pharmaceuticals has two new classification products in review, neither of which has been approved.
    Latest Study: NEJM Publishes Bayer's Important Phase 3 Clinical Results: DKD Progress Reduced by 18% CV Risk by 14% Bayer's Key Clinical Trial FIDELIO-DKD Results in Therapy Finderenone.
    study showed that finerenone had significant kidney and cardiovascular benefits for people with type 2 diabetes who combined chronic kidney disease, and that finerenone slowed the progression of kidney disease by 18 percent over a medium 2.6-year period compared to current standard treatments.
    results were published simultaneously in NEJM.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.